Ozempic denials in California external review
In the California DMHC record, independent physician reviewers decided 148 published external-review cases involving Ozempicand overturned the plan’s denial in 67.6%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 72 | 75% |
| Pre-diabetes | 23 | 34.8% |
| Type 2 Diabetes | 20 | 85% |
| Type 2 Diabetes Mellitus | 18 | 88.9% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 116 | 69.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 32 | 59.4% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Ozempic. Obesity is defined as having a body mass index (BMI) over 30 kg/m2 and is associated with an increased risk of diabetes, hypertension, hyperlipidemia, stroke, and malignant tumors. Obesity is a chronic disease for which medication-assisted weight loss is indicated in conjunction with lifestyle therapy for patients who are at risk for developing type 2 diabetes mellitus. The STEP 8 clinical trial compared the efficacy and safety profile of semaglutide versus liraglutide for the treatment of patients with overweight or obesity. The authors found that semaglutide resulted in significantly greater weight loss than liraglutide and greater improvements in several cardiometabolic risk factors.
Findings: The physician reviewer found that an enrollee has requested authorization and coverage for Ozempic. Obesity is a disease associated with a significant increase in mortality and many health risks, including type 2 diabetes mellitus, hypertension, dyslipidemia, and coronary heart disease. Weight loss in patients with obesity is associated with a reduction in mortality. The American Association of Clinical Endocrinologists (AACE) guidelines for the medical care of patients with obesity report that patients with obesity should be considered for treatment with weight-loss medication combined with lifestyle therapy when necessary to achieve sufficient improvements in lipids such as elevated triglycerides and reduced high-density lipoprotein (HDL-C).
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Ozempic. The U.S. Food and Drug Administration (FDA) approved the use of Ozempic, known generically as semaglutide, for lowering blood sugar in patients with type 2 diabetes mellitus based on the results from a clinical research program that included 8,000 patients, all with a history of type 2 diabetes mellitus, that showed a substantial decrease in hemoglobin (Hb) A1C levels when Ozempic was added to other standard therapies. Non-diabetic patients were excluded from the research trial. While the trial also showed evidence of weight loss in patients with type 2 diabetes on Ozempic, the FDA does not approve the use of Ozempic for weight loss.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Ozempic pen. This patient has a history of class 1 obesity. The U.S. Food and Drug Administration (FDA) approved semaglutide under the brand name Ozempic in 2017 to lower blood sugar in patients with type 2 diabetes mellitus. The FDA’s approval of Ozempic was based on a study that demonstrated a substantial decrease in the hemoglobin A1c level of patients with type 2 diabetes mellitus when treatment with Ozempic was added in conjunction with other standard therapies. Notably, nondiabetic patients were excluded from the study and only patients with a hemoglobin A1c level of 7% or more were eligible to participate.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Ozempic — and what reviewed cases show
Ozempic (semaglutide) is FDA-approved for: type 2 diabetes. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Indication mismatch
Ozempic is approved for type 2 diabetes; the weight-management version of semaglutide is Wegovy. Requests coded to obesity or prediabetes rather than type 2 diabetes are the classic Ozempic denial — and the published outcomes show reviewers back plans on true off-label weight-loss requests far more often than on diabetes requests.
Step therapy before GLP-1 coverage
Metformin-first requirements dominate. A denial for “step therapy not met” is usually a documentation gap — the trials happened but never made it into the prior-auth request.
Supply-driven quantity and refill denials
Dose titration and shortage-era substitutions produce quantity-limit and refill denials that have nothing to do with medical necessity. These are process denials and get fixed by exception requests more than by argument.
Plans must maintain an exception process for their step-therapy rules. Documented failure or intolerance of metformin or other preferred agents — stated by the prescriber with specifics — is the standard winning ground.
Evidence cited in overturned Ozempic decisions
- Anchor the appeal to the type 2 diabetes diagnosis: codes, A1C trend, current regimen, and the clinical goal Ozempic serves.
- List every preferred agent already tried, with outcomes — that single paragraph defeats most step-therapy denials.
- If the real goal is weight management without diabetes, the on-label semaglutide product is Wegovy; appeals argue far better on-label.
- For patients stable on Ozempic facing a formulary change: continuity-of-care rules in many states and plans protect ongoing therapy — invoke them.
The published California record contains 148 external-review decisions involving Ozempic; 67.6% were overturned. This historical rate does not predict another case. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Ozempic, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY